Yes but many people that have had kids get Alzheimer's. AD isnt aggressively selected against because it is only deleterious past reproductive age. It's true but AD is likely not one disease but is many different…
This is really good point. People underestimate he degree failed trials have value in understanding the basic science behind diseases, especially mechanistically complex ones.
I mean for AD it could perhaps be useful (of course it would not work for most other diseases) but legally that is very dicey because of informed consent. TBH we are not even sure if AD is one even one disease or if it…
Yeah I was looking for that but didn't find it in the paper, someone else here linked to pubchem in this thread. It's 3-(4-pyridinyl)-2-(napthylmethyl)-pyrazole N-oxide or something like that. My IUPAC is a bit rusty
Shouldn't be too bad. My gut would be toa naphthalene acetic acid ester, treat with LDA, add (4-pyridinyl)acetaldehyde to get a diketone by claisen-type condensation, then treat with hydroxylamine then reflux with…
Also you can cut them open when you are done. Can't do that to people. Sometimes you need biochemical tests and imaging very quickly post mortem to avoid changes in protein postranslational modifications. This is…
Then your get dropout problems and by the time there is an effect you don't have the statistical power to detect it. You need 3-6 months on an AD, psychiatic, metabolic, or autoimmune drug to see a Real effect so that…
I work in the side of academia that feeds drug leads to pharma and have seen this process. The big problem aside from time is cost and scale. You might start with either a million compound in silico 10000 compounds in a…
Well for the studios the art is the product. For researchers the ideas and data are the product and the writing is packaging. It's not a perfect analogy but it gets across why I personally don't get up in arms about…
Yes but many people that have had kids get Alzheimer's. AD isnt aggressively selected against because it is only deleterious past reproductive age. It's true but AD is likely not one disease but is many different…
This is really good point. People underestimate he degree failed trials have value in understanding the basic science behind diseases, especially mechanistically complex ones.
I mean for AD it could perhaps be useful (of course it would not work for most other diseases) but legally that is very dicey because of informed consent. TBH we are not even sure if AD is one even one disease or if it…
Yeah I was looking for that but didn't find it in the paper, someone else here linked to pubchem in this thread. It's 3-(4-pyridinyl)-2-(napthylmethyl)-pyrazole N-oxide or something like that. My IUPAC is a bit rusty
Shouldn't be too bad. My gut would be toa naphthalene acetic acid ester, treat with LDA, add (4-pyridinyl)acetaldehyde to get a diketone by claisen-type condensation, then treat with hydroxylamine then reflux with…
Also you can cut them open when you are done. Can't do that to people. Sometimes you need biochemical tests and imaging very quickly post mortem to avoid changes in protein postranslational modifications. This is…
Then your get dropout problems and by the time there is an effect you don't have the statistical power to detect it. You need 3-6 months on an AD, psychiatic, metabolic, or autoimmune drug to see a Real effect so that…
I work in the side of academia that feeds drug leads to pharma and have seen this process. The big problem aside from time is cost and scale. You might start with either a million compound in silico 10000 compounds in a…
Well for the studios the art is the product. For researchers the ideas and data are the product and the writing is packaging. It's not a perfect analogy but it gets across why I personally don't get up in arms about…